Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.66 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.66 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.63 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21853029 | 1.00 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL19953649 | 1.00 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGB8 | |
| Hydrochloric Acid SCHEMBL21853132 | 0.99 | ITGAV (0.64) | ITGAVITGB3ITGB6ITGB8 | |
| Hydrochloric Acid SCHEMBL28570633 | 0.99 | ITGAV (0.64) | ITGAVITGB3ITGB6ITGB8 | |
| Hydrochloric Acid SCHEMBL21853057 | 0.99 | ITGAV (0.64) | ITGAVITGB3ITGB6ITGB8 | |
| Hydrochloric Acid SCHEMBL21853055 | 0.99 | ITGAV (0.64) | ITGAVITGB3ITGB6ITGB8 | |
| Hydrochloric Acid SCHEMBL21853130 | 0.99 | ITGAV (0.64) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6790599 | 0.91 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL26971216 | 0.91 | ITGAV (0.61) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL26035895 | 0.88 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230060422-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230055657-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2021127466-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127483-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| EP-3509590-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20180093984-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| WO-2018049068-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6784190-B2 | USEFUL FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, TUMOR, ATHEROSCLEROSIS, INFLAMMATION, WOUND HEALING, VIRAL DISEASEDISEASE, TUMOR | MERCK & CO., INC. | 2004-08-31 | — | — | US | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1040098-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ITGAV 8/4885ITGB3 11/4885ITGB6 2/4885 |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGB6 17/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | ITGAV 1/4885ITGB3 2/4885ITGB6 9/4885 |
| US-20230060422-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | SLC10A1, SLC5A1, ITGA1 | ITGAV 11/4885ITGB3 27/4885ITGB6 20/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGB6 17/4885 |
| US-20230055657-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NR1H4, ITGA1, ITGA4 | ITGAV 10/4885ITGB3 14/4885ITGB6 16/4885 |
| US-20180093984-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGB6 17/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ITGAV 8/4885ITGB3 11/4885ITGB6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.